ATRC · AtriCure, Inc.
$55.14
+1.55 (+2.89%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$2.93B
Shares
50.87M
Volume · Oct 2
1.62M
Avg daily vol (3M)
1.08M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$55.14
Open$52.51
Day$52.00–55.25
52W close$25.86–60.77
Avg vol 30d1.4M
Short int4.3M · 8.4% float · 3.6d
Short vol59%
Last earningsJul 23, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 27
Up next
Next earnings call
Oct 17, 2026
Est · unconfirmed
· in 2 wks
filed Jul 27, 2026
call held Jul 23, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$569.62M
Trailing 12 months
Net income (TTM)
$10.55M
Trailing 12 months
Revenue growth YoY
+12.8%
Year over year
Operating margin
2.3%
Trailing 12 months
P / E (TTM)
255.2
Trailing earnings · reciprocal yield 0.4%
FCF yield
1.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+56.6%
Trailing year
Short interest
8.4%
Latest settlement · 3.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+52%
above
Price vs 50-day avg
+12%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
84%
mid-range
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+92%
trailing
YTD return
+39%
this year
Relative strength
+80%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $49 › 200d $36 — 50d above 200d
Institutional flow
Accumulating
1 of 253 funds reported for Sep 30 · net +43 sh shares
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Rising
8.41% of float · ▲ +3.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
Gross margin
199%
contracting
EPS growth
+75%
Y/Y
Free cash flow
$48.3M
Valuation
P/E 273.9
rich
Balance sheet
$28.3M
net cash
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Revenue
· full year 2026
Initiated
$602M – $610M
prior FY $534.53M
midpoint +13.4% Y/Y
Adjusted EBITDA
· full year 2026
Initiated
$85M – $89M
Net income per share
· full year 2026
Initiated
$0.05 – $0.13
prior FY $-0.24
midpoint +137.5% Y/Y
Adjusted earnings per share
· full year 2026
Initiated
$0.24 – $0.32
Guided vs delivered
· last 6 settled
Revenue
full year 2024
guided $456M – $461M
$465.31M
Beat +1.5%
Full year 2023 revenue
full year 2023
guided $394M – $396M
$399.25M
Beat +1.1%
Revenue
full year 2022
guided $315M – $330M
$330.38M
Beat +2.4%
Revenue
full year 2021
guided $270M – $275M
$274.33M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+52%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $49 › 200d $36 — 50d above 200d
Institutional flow
Accumulating
1 of 253 funds reported for Sep 30 · net +43 sh shares
Insider flow
Distributing
Net -$2.4M over 90 days · 100% sells
Short interest
Rising
8.41% of float · ▲ +3.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
253 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26
Now $55 · 84%
Range high $61
vs 200-day avg +52%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Appendage management revenue | $51.61M | Three Months Ended June 30, 2026 filing | — |
| Minimally invasive ablation revenue | $6.03M | Three Months Ended June 30, 2026 filing | — |
| Open ablation revenue | $40.89M | Three Months Ended June 30, 2026 filing | — |
| Pain management revenue | $27.06M | Three Months Ended June 30, 2026 filing | — |
| Total International revenue | $28.02M | Three Months Ended June 30, 2026 filing | — |
| Total United States revenue | $125.59M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRC
this stock
AtriCure, Inc.
|
$2.93B | +39.4% | +15.4% | 273.9 | 8.4% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRC | -5.6% | +5.1% | +92.4% | -1.9% | +39.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.3% | +5.6% | +80.2% | -2.8% | +26.5% |